Is Latuda (lurasidone) safe to use during pregnancy?

Latuda Use During Pregnancy: Limited Safety Data with No Clear Teratogenic Signal

Latuda (lurasidone) can be considered during pregnancy when the benefits of treating severe psychiatric illness outweigh potential risks, as there is no clear evidence of teratogenicity, though human data remain limited. 1

Key Safety Information from FDA Labeling

The FDA drug label for Latuda provides critical guidance 1:

• No human pregnancy studies exist - the available data are insufficient to determine drug-associated risk of birth defects or miscarriage
• Animal studies are reassuring - no teratogenic effects were observed in rats and rabbits at doses up to 1.5-6 times the maximum recommended human dose
• Third-trimester risk exists - neonates exposed to antipsychotics in the third trimester are at risk for extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorders)
• Neonatal monitoring is essential - infants require observation for these symptoms, which vary in severity and may require prolonged hospitalization

Human Pregnancy Registry Data

The most robust human data comes from the National Pregnancy Registry for Psychiatric Medications 2:

• 134 lurasidone-exposed pregnancies were analyzed prospectively
• Major malformation rate: 2.19% compared to 1.77% in unexposed controls
• Odds ratio: 1.24 (95% CI 0.36-4.32) - not statistically significant
• No specific malformation patterns were identified
• The study concluded lurasidone does not appear to be a major teratogen, though more data are needed

Critical Clinical Considerations

Risk-Benefit Framework

The decision to use Latuda during pregnancy must weigh:

Risks of untreated psychiatric illness:

• Severe mental illness itself poses risks to maternal and fetal health
• Untreated bipolar disorder or schizophrenia can lead to poor prenatal care, substance use, suicide risk, and impaired maternal-infant bonding

Risks of medication exposure:

• Potential (though unproven) teratogenic effects
• Third-trimester neonatal adaptation syndrome
• Possible metabolic effects (though data specific to pregnancy are lacking)

Pharmacokinetic Changes During Pregnancy

One case report demonstrates important dosing considerations 3:

• Lurasidone concentrations decreased substantially during pregnancy (0-4.7 ng/mL) compared to postpartum levels (10-12 ng/mL)
• This patient required a 40 mg daily dose increase during the second trimester due to worsening anxiety and depressive symptoms
• Therapeutic drug monitoring may be warranted to maintain efficacy during pregnancy

Metabolic Monitoring

While not specific to pregnancy, second-generation antipsychotics carry metabolic risks 4:

• Meta-analysis shows SGAs (including lurasidone) associated with 1.4 times higher risk of gestational diabetes
• Screen for gestational diabetes in all pregnant women taking antipsychotics
• Monitor weight gain, blood pressure, and glucose throughout pregnancy

Practical Management Algorithm

Pre-conception:

1. Discuss pregnancy plans with all women of reproductive age on Latuda
2. Enroll in the National Pregnancy Registry (1-866-961-2388 or womensmentalhealth.org)
3. Optimize psychiatric stability before conception
4. Consider whether medication can be safely discontinued or reduced

During pregnancy:

1. Continue Latuda if psychiatric stability requires it - do not abruptly discontinue
2. Use the lowest effective dose
3. Consider therapeutic drug monitoring, especially if symptoms worsen in second/third trimester
4. Screen for gestational diabetes at 24-28 weeks
5. Coordinate care with maternal-fetal medicine and psychiatry
6. Plan for neonatal monitoring at delivery

Third trimester/delivery:

1. Alert neonatology team to antipsychotic exposure
2. Monitor neonate for at least 48-72 hours for extrapyramidal symptoms and withdrawal
3. Do not discontinue medication to avoid third-trimester exposure - the risk of maternal decompensation outweighs neonatal adaptation risks

Postpartum:

1. Recognize that lurasidone concentrations increase postpartum 3
2. May need to reduce dose back to pre-pregnancy levels
3. Monitor closely for postpartum psychiatric decompensation (high-risk period)

Common Pitfalls to Avoid

• Do not discontinue abruptly upon learning of pregnancy - this increases risk of psychiatric decompensation
• Do not assume pre-pregnancy doses remain adequate - physiologic changes may require dose adjustments
• Do not fail to coordinate with obstetrics - shared decision-making is essential
• Do not neglect metabolic screening - gestational diabetes risk is elevated with SGAs

Breastfeeding Considerations

The FDA label notes 1:

• No human lactation studies exist
• Lurasidone is present in rat milk
• The decision to breastfeed should consider the mother's clinical need for Latuda and potential effects on the infant
• Benefits of breastfeeding should be weighed against unknown risks of infant exposure

In clinical practice, if Latuda is essential for maternal mental health, the benefits of both medication continuation and breastfeeding may outweigh theoretical risks, but this requires individualized shared decision-making.